GlassScriptPhysician profile
Heather B Minto
NPI 1073807624
$2,998.80
in general payments reported to CMS, 2019-2025
22 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $190 · 2021: $37.13 · 2022: $180 · 2023: $529 · 2024: $731 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156 · Education: $80.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.16 |
| Education | $80.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $659.51 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $477.98 | 2019-2025 | Tezspire, Fasenra |
| Csl Behring | $393.68 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $372.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $162.46 | 2019-2025 | |
| Amgen INC. | $154.91 | 2022-2025 | Tezspire |
| Kaleo, INC. | $127.90 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $115.02 | 2023-2025 | Cuvitru, Eohilia |
| Pharming Healthcare, INC. | $77.45 | 2023-2025 | Ruconest |
| Genentech USA, INC. | $72.86 | 2023-2024 | Xolair |
| Glaxosmithkline, LLC. | $71.33 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $69.53 | 2019-2025 | Xembify |
| Biocryst US Sales Co., LLC | $48.69 | 2024-2025 | Orladeyo |
| Kedrion Biopharma, INC. | $36.43 | 2024 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Teva Pharmaceuticals USA, INC. | $32.07 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $26.88 | 2019 | |
| Greer Laboratories, INC. | $26.61 | 2023 | Palforzia |
| Alk-Abello, INC | $17.64 | 2019 | |
| Pfizer INC. | $15.24 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.00 | 2025 | Alvesco |
| Bio Products Laboratory USA, INC. | $13.99 | 2019 | |
| Shire North American Group INC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Minto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.